J&J Says Penalties In Arkansas Risperdal Case ‘Excessive,’ Seeks New Trial
This article was originally published in The Pink Sheet Daily
Argues that Arkansas Medicaid spent less than $10 million on Risperdal, but the fine imposed by a state judge for deceptive marketing practices would exceed $1.2 billion.
You may also be interested in...
Court throws out $1.2 billion award to the state of Arkansas over Risperdal promotions.
As the result of a multiple technology appraisal from Britain’s U.K.’s reimbursement watchdog, NICE, three ovarian cancer drugs will disappear from the publicly funded NHS.
J&J’s agreement with state AGs, which involves payments totaling $181 million, sets a number of restrictions on the company’s marketing practices for atypical antipsychotics that will be in effect for five years.